Medical Company Receives Major Patent Approval For Binge Behavior Treatment

Clearmind Medicine Inc., a clinical-stage biotech company, has marked a notable advancement in its research and development efforts with the recent patent approval in Hong Kong. The company, listed on both Nasdaq (CMND) and the Frankfurt Stock Exchange (FSE: CWY0), is at the forefront of developing novel psychedelic-derived therapeutics aimed at addressing major health issues that are currently underserved by traditional treatments. The patent granted by the Hong Kong Patent Office represents a critical step forward for Clearmind, especially within its program focusing on regulating binge behaviors through proprietary MEAI-based treatments. $Clearmind Medicine(CMND.US)$